your questions → straight answers
PT-141 FAQ: bremelanotide, answered plainly.
The questions people actually search, each with a short, cited answer.
How does PT-141 compare to flibanserin and testosterone for women?
Bremelanotide and flibanserin are the two FDA-approved medications for premenopausal HSDD, and testosterone is used off-label. A 2025 comparative analysis [Vereecken S, et al., 2025] and a 2025 review [How A, Simon JA, 2025] contrast their effect profiles and place in therapy: PT-141 is an as-needed injection, flibanserin a daily pill, testosterone an off-label third option.
Is PT-141 better than PDE-5 inhibitors for erectile dysfunction?
They work differently and PT-141 is not approved for erectile dysfunction. PT-141 acts centrally on brain MC4R, while PDE-5 inhibitors act peripherally on vascular smooth muscle [1]. The male/erectile evidence is early-phase; a review situates melanocortin agonists among investigational, centrally acting approaches [7]. "Better" isn't established.
What is PT-141?
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide analogue of alpha-MSH that activates central melanocortin MC3R/MC4R receptors [1]. It was FDA-approved in 2019 for one use only: HSDD in premenopausal women [6]. All other uses are off-label.
What is PT-141 peptide?
The PT-141 peptide is a 1,025 Da cyclic seven-amino-acid lactam — sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, formula C50H68N14O10 [1]. It is a synthetic analogue of the natural hormone alpha-MSH and is the same molecule marketed under the name bremelanotide [6].
What does the PT-141 peptide do?
It activates brain melanocortin MC4R (and MC3R) circuits linked to sexual desire and arousal [1]. In other words, it acts on the neural circuitry of sexual motivation — the "wanting" — rather than on blood flow, which is how it differs from erectile blood-flow drugs.
What is PT-141 used for?
Its only FDA-approved use is acquired, generalized HSDD in premenopausal women [6]. All other uses — in men, for erectile dysfunction, in postmenopausal women, or for sexual performance — are off-label and not supported by the approval. The male evidence remains early-phase and investigational [7].
Is PT-141 the same as bremelanotide?
Yes. PT-141 is the development and research designation; bremelanotide is the international nonproprietary name (INN) for the identical molecule, carried on FDA approval NDA 210557 [6]. Same compound, two names — research label versus approved-drug name.
What is bremelanotide?
Bremelanotide is the approved-drug name for PT-141, a melanocortin MC3R/MC4R agonist [1]. It was approved in June 2019 as a 1.75 mg subcutaneous as-needed injection for HSDD in premenopausal women [6].
How does PT-141 work?
By switching on MC4R in hypothalamic circuits such as the medial preoptic area, which is thought to engage dopamine pathways that govern sexual desire [1]. A 2022 fMRI study showed MC4R activation altered central sexual brain processing in women with HSDD [5].
What receptors does PT-141 act on?
Chiefly the melanocortin 4 receptor (MC4R), with MC3R as a secondary central target [1]. Separately, MC1R activation in the skin underlies the hyperpigmentation reported with repeated, frequent dosing [6]. Different receptors, different effects.
Does PT-141 work through the brain or through blood flow?
Through the brain. Unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle to support blood flow, PT-141 works centrally on the neural circuitry of sexual motivation [1]. This is the single most important thing to understand about how it differs from erectile drugs.
What is a melanocortin receptor agonist?
A compound that activates melanocortin receptors (MC1R–MC5R), which normally respond to peptides such as alpha-MSH [1]. PT-141 targets the central MC3R/MC4R subtypes in the brain, which is why its main effect is on sexual desire rather than on a peripheral tissue.
Does PT-141 increase testosterone?
No. PT-141 does not act via the HPG (hormonal) axis and does not directly raise testosterone — a common point of confusion. It works on central melanocortin receptors in the brain [1]. If desire changes, it is via that brain circuitry, not via a testosterone increase.
How is PT-141 different from PDE-5 inhibitors?
PDE-5 inhibitors (such as sildenafil) act peripherally on vascular smooth muscle to improve erectile blood flow; PT-141 acts centrally on brain melanocortin receptors involved in sexual desire [1]. They target different problems by different routes — desire versus blood flow.
What is the PT-141 dosage?
The approved label specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated activity, no more than one dose per 24 hours and no more than 8 doses per month [6]. This is reported as the label and trial dose, not a recommendation for any individual.
How much PT-141 should I take?
This site reports only what trials and the label studied — 1.75 mg subcutaneous as-needed in the approved population [3][6] — and does not recommend a dose for any individual. Dosing decisions belong with a qualified clinician, not a website.
How much PT-141 to inject?
The approved subcutaneous dose studied was 1.75 mg per administration; Phase 2 dose-finding in women evaluated 0.75, 1.25, and 1.75 mg before that dose was carried forward [3][6]. Reported here as findings, not as a protocol to follow.
What is the PT-141 dosage for women?
In premenopausal women with HSDD, the approved label dose is 1.75 mg subcutaneous as-needed (maximum one dose per 24 hours, 8 doses per month) — the dose used in the RECONNECT Phase 3 trials [3][6]. Reported as the studied regimen, not advice.
How do you reconstitute PT-141?
The approved bremelanotide product is supplied as a prefilled subcutaneous autoinjector and is not reconstituted [6]. Lab-research "PT-141" lyophilized material is a separate, non-finished form, and this site reports no preparation protocol for human use.
How do you take PT-141?
In the approved indication, bremelanotide is self-administered as a single subcutaneous injection as needed, at least 45 minutes before anticipated activity [6]. Reported as the studied regimen, not as advice to self-administer anything.
How often can you take PT-141?
The label specifies no more than one dose per 24 hours and no more than 8 doses per month [6]. Exceeding that frequency is associated with hyperpigmentation and appetite/weight effects in research, which is part of why the cap exists [6].
What is the approved bremelanotide dose?
1.75 mg subcutaneous, as needed, with a maximum of one dose per 24 hours and no more than 8 doses per month, per the US prescribing information [6]. It is given at least 45 minutes before anticipated activity.